Senescence and cancer - role and therapeutic opportunities

  • Nat Rev Clin Oncol. 2022 Oct;19(10):619-636. doi: 10.1038/s41571-022-00668-4.
Clemens A Schmitt  #  1  2  3  4  5 Boshi Wang  #  6 Marco Demaria  7
Affiliations
  • 1. Charité Universitätsmedizin Berlin, Medical Department of Hematology, Oncology and Tumour Immunology, and Molekulares Krebsforschungszentrum-MKFZ, Campus Virchow Klinikum, Berlin, Germany.
  • 2. Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • 3. Johannes Kepler University, Linz, Austria.
  • 4. Kepler University Hospital, Department of Hematology and Oncology, Linz, Austria.
  • 5. Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), Partner site Berlin, Berlin, Germany.
  • 6. European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), University of Groningen (RUG), Groningen, the Netherlands.
  • 7. European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), University of Groningen (RUG), Groningen, the Netherlands. [email protected].
  • # Contributed equally.
Abstract

Cellular Senescence is a state of stable, terminal cell cycle arrest associated with various macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells into senescence can act as a barrier to tumorigenesis and, thus, could in principle constitute a desired outcome for any Anticancer therapy. Paradoxically, studies published in the past decade have demonstrated that, in certain conditions and contexts, malignant and non-malignant cells with lastingly persistent senescence can acquire pro-tumorigenic properties. In this Review, we first discuss the major mechanisms involved in the antitumorigenic functions of senescent cells and then consider the cell-intrinsic and cell-extrinsic factors that participate in their switch towards a tumour-promoting role, providing an overview of major translational and emerging clinical findings. Finally, we comprehensively describe various senolytic and senomorphic therapies and their potential to benefit patients with Cancer.